{"id":297,"date":"2008-12-26T10:17:37","date_gmt":"2008-12-26T09:17:37","guid":{"rendered":"http:\/\/localhost\/new\/htb\/?p=297"},"modified":"2013-08-23T12:56:40","modified_gmt":"2013-08-23T12:56:40","slug":"statin-use-in-hiv-positive-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/297","title":{"rendered":"Statin use in HIV-positive  patients"},"content":{"rendered":"<p><strong>Satyajit Das, HIV i-Base<\/strong><\/p>\n<p><strong>The effectiveness and adverse events related to statins among HIV-positive patients was investigated by Singh and colleagues from University of Washington, Seattle, in an observational cohort study of all patients in two large clinical settings.<\/strong><\/p>\n<p>Over 700 patients starting their first statin were followed for a median of 19 months. Prescribed statins included atorvastatin (n=303), pravastatin (n=280), and rosuvastatin (n=98).<\/p>\n<p>One year after starting statins, after controlling for baseline lipid values, and demographic and clinical characteristics, patients on atorvastatin and rosuvastatin had a significantly greater decrease in TC (-14.5 and -18.0 mg\/dL, both p&lt;0.001) and LDL (-14.0 and -11.2 mg\/dL, both p&lt;0.02) than those on pravastatin. Patients on rosuvastatin had a greater decline in triglyceride levels. Adverse event rates were similar for atorvastatin (4.6%), pravastatin (4.2%), and rosuvastatin (3.9%). NCEP target levels for LDL at 1 year were achieved by 68% on atorvastatin and 69% on rosuvastatin vs 55% on pravastatin (p=0.01).<\/p>\n<p>The authors concluded &#8220;Despite large reductions, many patients did not reach a target goal. Evaluation of the safety and effectiveness of additional lipid lowering agents like ezetemibe or fibrates needs further exploration&#8221;.<\/p>\n<p>Reference:<\/p>\n<p>Singh et al. Effectiveness of individual HMG CoA reductase inhibitors (Statins) in HIV-infected patients in clinical care. 48th ICAAC, 25-28 October 2008. Washington. Abstract H-2303.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Satyajit Das, HIV i-Base The effectiveness and adverse events related to statins among HIV-positive patients was investigated by Singh and colleagues from University of Washington, Seattle, in an observational cohort study of all patients in two large clinical settings. Over &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,8,27],"tags":[102],"class_list":["post-297","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-side-effects","category-weight-diabetes-metabolic-complications","tag-icaac-48th-2008"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=297"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/297\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}